PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment femoropopliteal disease with minimally-invasive endovascular solutions.
PQ Bypass is a former Company-In-Residence at the Fogarty Institute for Innovation and is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker and also have extensive experience developing medical devices for venture-backed startups such as Evalve, AccessClosure, and DVI.
Our goal is to reduce patient hardship along with the morbidity and mortality associated with more invasive procedures and to ultimately improve the quality-of-life for patients with peripheral artery disease
The underlying technology and technique used in the percutaneous PQ Bypass procedure was co-developed by two world-renowned cardiologists and innovators, Dr. James Joye (El Camino Hospital, Mountain View, California) and Dr. Richard Heuser (St. Luke’s Hospital, Phoenix, Arizona), who are internationally recognized experts in peripheral artery disease (PAD).
In March 2017, PQ Bypass received CE (Conformité Européenne) Mark approval for the DETOUR™ System.
In August 2017, Frost & Sullivan recognized PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award for the DETOUR procedure.
In November 2017, PQ Bypass received conditional approval of their IDE for the DETOUR™ System.
Richard Ferrari – CEO
Rich is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Bio-Technology. Rich has been a successful CEO of two publicly traded medical technology companies, Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters, and CardioThoracic Systems (CTS) , which pioneered off-pump bypass surgery. He also co-founded the Medical Technology Group which spun-out Integrated Vascular Systems. Previously Mr. Ferrari held the positions of Executive Vice President and General Manager of ADAC Laboratories. In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to startup medical technology companies. Rich is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.
Heather Simonsen – Senior Vice President & General Manager
Heather has almost 30 years of experience in the healthcare industry. She has served in senior roles for venture-funded medtech startups and Fortune 500 companies such as Abbott and Johnson & Johnson. Heather completed the Executive Program at Dartmouth’s Tuck School of Business and holds an MBA from Chicago’s DePaul School of Business. She has held board positions with the Medical Marketing Association, Healthcare Businesswomen’s Association, and is on the founders’ board of advisors for the Stanford University-affiliated StartX Accelerator. Heather currently serves on the Board of Directors for Sanarus Technologies, Inc., a commercial-stage company pioneering a minimally invasive cryoablation treatment for breast tumors.
Pharoah Garma- Vice President, Regulatory Affairs
Pharoah has over 13 years of regulatory experience with a focus on cardiovascular medical devices and combination products. With regulatory leadership experience at companies including Medtronic and Biotronik, most recently Pharoah presided over the regulatory team at Spectranetics Corp (now Philips Image Guided Therapy Devices), where she led the group to a significant number of approvals, and successfully completed PMA and CE Mark trials. She spent the first half of her career as Senior Lead FDA Reviewer in the Interventional Cardiology Devices Branch. Pharoah holds BS and Meng degrees in Biomedical Engineering from Syracuse University.
Ron Steckel- (Acting) Chief Operating Officer
Ron’s extensive experience with start-ups encompasses a broad range of corporate strategies, novel and disruptive technologies, diverse management teams and changes in the clinical, regulatory and reimbursement landscape. Ron has held multiple operating leadership roles, including: President & CEO of Pulmonx, Chief Operating Officer of FoxHollow, and Vice-President of Operations for Iridex. His experience comprises over 35 years of domestic and international positions in the medical device, diagnostics and pharmaceutical industries including major corporations and private companies.
Steve Van Dick – (Acting) Chief Financial Officer
Steve Van Dick is a strategic financial and accounting executive with a winning record of transitioning early stage companies to commercialization through astute financial management. Respected in the medical device startup community as financial startup subject matter expert, he develops and leads comprehensive, world-class financial and accounting groups credited for propelling startup companies forward. Across his career Steve has played a key role on the Executive Leadership Teams that successfully completed three separate Initial Public Offering (IPOs) and three mergers/integrations.
Richard Ferrari / PQ Bypass
Stanton Rowe / NXT Biomedical
Seroba Life Sciences
Seroba Life Sciences